Liquid Biopsy
News and reporting on cell-free DNA testing.
Metastatic Prostate Cancer Study Underscores Precision Medicine Potential in Diverse US Veterans
Researchers profiled somatic changes in tumor samples from thousands of US veterans with metastatic prostate cancer, identifying alterations with varied representation by ancestry.
New Grail Publication Explores Optimal Liquid Biopsy MCED Test Interval for Mortality Impact
Premium
Company investigators calculated the expected reduction in late-stage cancer diagnoses and projected drops in mortality for different screening schedules in different models of cancer growth.
Natera Ramping up R&D, Commercial Spending as Q1 Product Revenues Rise 37 Percent, Beat Estimates
Premium
The firm trimmed its Q1 net loss and has begun investing heavily in R&D and commercial operations to drive future growth.
Precision oncology company Inocras launched a clinical MRD test last week that uses Ultima's platform to sequence circulating tumor DNA from blood.
Personalis Q1 Revenues up 6 Percent as Firm Anticipates First MRD Reimbursement Wins
The company beat Wall Street expectations on the top and bottom lines, attributing its growth to both clinical and pharma adoption of its residual cancer testing platform.